INTERIM REPORT JANUARY-SEPTEMBER 2023

THIRD QUARTER, JULY-SEPTEMBER 2023

• Net sales amounted to MSEK 0.0 (0.0)

• Operating loss (EBIT) amounted to MSEK -5.6 (-4.5)

• Net loss amounted to MSEK -5.5 (-4.5)

• Net cash flow amounted to MSEK -4.6 (-7.4)

• EPS before and after dilution amounted to SEK -0.06 (-0.17)

 
JANUARY- SEPTEMBER 2023

• Net sales amounted to MSEK 0.0 (0.0)

• Operating loss (EBIT) amounted to MSEK -17.8 (-20.5)

• Net loss amounted to MSEK -18.3 (-20.5)

• Net cash flow amounted to MSEK 7.7 (-9.1)

• EPS before and after dilution amounted to SEK -0.32 (-0.87)

 
Significant events
During the reporting period

• In August, Emplicure hired Johan Magné as Sales Director with a long background in Swedish Match to drive the company's sales of smååTM.

• In September, the company received a research grant of MSEK 1.0 from Vinnova, Sweden's Innovation Authority, within the framework of the competence center SweDeliver.

• Also in September, the company announced that the company, through its subsidiary Amplicon, initiates a collaboration on a clinical study with CTC Clinical Trial Consultants AB, a recognized contract research organization (CRO).

 
After the reporting period

• In October the company was informed that a buyout consortium had agreed to acquire over 90 per cent of the shares in Emplicure and intends to initiate squeeze-out proceedings.

• In November Emplicure announced the hiring of a marketing manager, Sophia Bailey

• In November the buyout consortium initiated squeeze-out proceedings and Emplicure applied for delisting. Nasdaq approved the delisting with the 27 November as the last trading day